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 Upregulation of the Expression of Infl ammatory 
and Angiogenic Markers in Human Adipocytes by a 
Synthetic Cannabinoid, JTE-907 
cloning of the cannabinoid receptors CB 1 and CB 2 
(nomenclature follows Alexander, Mathie, and 
Peters  [1] ), and subsequently the discovery of the 
fi rst endocannabinoids, anandamide and 2-ara-
chidonoylglycerol (2-AG)  [2 – 4] . More recently, 
other putative ECS receptors, such as TRPV1 
(transient receptor potential cation channel, sub-
family V, member 1) and GPR55 (G protein-cou-
pled receptor 55), have been recognized  [5,  6] . 
The tissues and organs where the various ECS 
receptors are expressed is still unclear, but in 
humans the CB 1 receptor is mainly expressed in 
the brain with some expression in a range of 
other tissues, including kidney, liver, lung, skele-
tal muscle, and adipose tissue  [7 – 9] . The TRPV1 
receptor is highly expressed in human sensory 
neurons  [10] , but it is also expressed in human 
adipose tissue  [11] . On the other hand, the CB 2 
receptor is expressed in macrophages  [12] and 
expression is also reported in the rat central 
nervous system  [13] , while there is some contro-
versy about its presence in human adipose tissue 
depots  [9,  11] . 
 Abbreviations 
 ▼ 
 AM251  N -(Piperidin-1-yl)-5-
(4-iodophenyl)-1-
(2,4-dichlorophenyl)-
4-methyl-1 H -pyrazole-3-
carboxamide 
 AM630  6-Iodo-2-methyl-1-[2-
(4-morpholinyl)ethyl]-1 H -indol-3-
yl](4-methoxyphenyl) methanone 
 Arachidonyl 
serotonin 
(A.S.) 
 N -[2-(5-Hydroxy-1H-indol-
3-yl)ethyl]-5,8,11,14-
eicosatetraenamide 
 JTE-907  N -(1,3-Benzodioxol-5-ylmethyl)-
1,2-dihydro-7-methoxy-2-oxo-
8-(pentyloxy)-3-
quinolinecarboxamide 
 Introduction 
 ▼ 
 The medical properties of marijuana ( Cannabis 
sativa ) led to the discovery of the endocannabi-
noid system (ECS) in the early 1990s, with the 
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 Abstract 
 ▼ 
 Infl ammation in adipose tissue is a characteris-
tic of obesity and the metabolic syndrome. It is 
suggested that the endocannabinoid system is 
involved in the regulation of infl ammatory and 
angiogenic processes within the tissue. Human 
subcutaneous preadipocytes (Zen Bio) were 
used as the source of human preadipocytes or 
adipocytes. Gene expression was examined 
by RT-PCR and real-time PCR. The secretion of 
infl ammation-related proteins was determined 
by an ELISA array. In experiments on adipocytes 
treated at day 14 post-diff erentiation, JTE-907, a 
synthetic cannabinoid, upregulated the expres-
sion of key infl ammatory markers  – IL-6, MCP-1 
and IL-1 β  – and angiogenic factors  – VEGF and 
ANGPTL4  – at 10  μ M after 20  h of treatment, 
having also increased the expression of TRPV1 
at 10  μ M. JTE-907 showed no eff ect after 4  h. 
The ELISA array showed a 2.6-fold increase in 
IL-6 protein release. The eff ect of JTE-907 was 
inhibited by AM251 (CB 1 antagonist), and par-
tially by arachidonyl serotonin (TRPV1 and FAAH 
antagonist). The CB 2 antagonist, AM630, partially 
upregulated the eff ect of JTE-907. Preadipocytes 
fed 14 days after 100  % confl uence exhibited 
downregulation of CB 1 , MCP-1, and IL-1 β , 20  h 
after having been exposed to JTE-907. CB 1 and 
TRPV1 receptors participate in the regulation 
of several infl ammatory and angiogenic factors 
in human adipocytes, indicating their potential 
value as targets for the treatment of disorders 
related to obesity. 
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 The list of ligands of the cannabinoid receptors is extensive and 
is divided into 3 categories: phytocannabinoids (from plants), 
endocannabinoids (endogenous cannabinoids), and synthetic 
cannabinoids (developed as putative drugs). JTE-907, which is in 
this last category, binds to CB 1 and CB 2 cannabinoid receptors 
with a higher affi  nity for the latter  [14] . This synthetic com-
pound appears to be an anti-infl ammatory or antiallergic agent 
 [15 – 17] . The ECS and its receptors CB 1 , TRPV1, and CB 2 have 
been linked to a wide range of functions, including: vascular and 
endocrine responses, neuroprotection and nociception, immune 
modulation, stress recovery, food intake, energy balance, and 
metabolic homeostasis  [18 – 20] . Of particular interest is the role 
of the ECS in appetite and the regulation of energy balance  [21] , 
CB 1 receptor blockade in animals and humans producing a 
reduction in body weight and an improvement of the comor-
bidities of obesity  [22,  23] . 
 Obesity is a major public health problem in most developed 
countries and in the UK, for example, 25  % of adults are now 
clinically obese with a BMI   ≥  30. Obesity is characterized by 
chronic low grade infl ammation  [24 – 26] and this has been 
linked to the development of the associated comorbidities, par-
ticularly the components of the metabolic syndrome  [27,  28] . 
Adipose tissue is a major site of infl ammation in obesity, with 
the adipocytes secreting a number of cytokines, chemokines, 
and other infl ammation-related factors, including those involved 
in angiogenesis  [26,  29] . Several studies have demonstrated the 
importance of the ECS in infl ammatory processes and angiogenic 
events; for example, in human macrophages  [30] , mouse obese 
models  [20] , mouse cutaneous tissue  [17] , rat mesenteric arter-
ies, and human cerebral artery endothelial cells  [17,  30,  31] . Lit-
tle is known, however, of the genes whose expression may be 
modulated through the endocannabinoid system. 
 The aim of the present study was to examine the eff ects of the 
ECS on the expression of key infl ammatory and angiogenic genes 
in human white adipocytes. The results suggest that CB 1 and 
TRPV1 receptors participate in the regulation of several impor-
tant infl ammatory and angiogenic factors in human adipocytes 
and preadipocytes. These key cannabinoid receptors could be a 
target for the pharmacotherapy of infl ammatory and angiogenic 
events within adipose tissue. 
 Materials and Methods 
 ▼ 
 Cell culture 
 Human subcutaneous preadipocytes and culture media were 
obtained from Zen-Bio (Durham, NC, USA) and cultured as previ-
ously  [32] . Cells were from 5 female patients of average age 45.6 
years and with a mean BMI of 27.9. The cells were plated at a 
density of 40  000 / cm 2 onto a 24-well plate and maintained in 
preadipocyte medium (PM) containing DMEM / Ham ’ s F-12 (1:1, 
v / v), 10  % fetal calf serum (FCS), 15  mM HEPES, 100  U / ml penicil-
lin, 100  μ g / ml streptomycin, and 0.25  μ g / ml amphotericin B at 
37  °  C in a humidifi ed atmosphere of 95  % air / 5  % CO 2 . The cells 
were induced at confl uence by incubation in diff erentiation 
medium composed of adipose medium (AM) supplemented 
with 0.25  mM isobutylmethylxanthine and 10  μ M of a PPAR γ 
agonist for 5 days. The cells were then cultured with AM con-
taining DMEM / Ham ’ s F-12 (1:1, v / v), 3  % FCS, 100  nM insulin, 
1  μ M dexamethasone, 100  U / ml penicillin, 100  μ g / ml streptomy-
cin, and 0.25  μ g / ml amphotericin B  [33] . The medium was 
changed every 3 days. 
 Preadipocytes (fed 14 days after 100  % confl uence) were exposed 
to JTE-907 (10  μ M) for 20  h. Fully diff erentiated cells at day 14 
post-induction were exposed to JTE-907 (1  μ M or 10  μ M) for 4 or 
20  h, and to AM251 (100  nM), A.  S. (arachidonyl serotonin, 10  μ M) 
and AM630 (10  μ M) (all reagents were from Tocris Bioscience, 
Bristol, UK). The cells were harvested in 500  ml TRI  ®  Reagent 
(Sigma-Aldrich, St. Louis, MO, USA). Culture media were also col-
lected. All incubations at each time point were performed in 
replicates of up to 6 wells. 
 RNA extraction and RT-PCR 
 Total RNA was isolated from cells using TRI  ®  reagent and treated 
with Turbo DNA-free ™ (Applied Biosystems / Ambion, Austin, TX, 
USA) according to the manufacturer ’ s instructions. 1  μ g of DNa-
seI-treated RNA was reverse transcribed to obtain cDNA with 
Reverse-iT 1st Strand Synthesis kit (Abgene, Epsom, UK) in the 
presence of anchored oligo dT in a total volume of 20  μ l. 
 Primers were designed using Primer Premier 5 software (Biosoft 
International, Palo Alto, CA, USA) and synthesized by MWG Bio-
tech (Ebersberg, Germany). Primer sequence, size of the ampli-
fi ed fragments, and optimal conditions of amplifi cation were as 
follows. 
 β actin (281  bp): 5 ′ -GTGGCATCCACGAAACTACCTT-3 ′ (forward), 
5 ′ -GGACTCGTCATACTCCTGCTTG-3 ′ (reverse), 23 cycles and 
annealing temperature 57  °  C; 
 CB 1 (298  bp): 5 ′ -CAGCGTGGCACCCAGAAGA-3 ′ (forward), 5 ′ -
CGGAAAGCGTGTCGCAGGT-3 ′ (reverse), 35 cycles and annealing 
temperature 60.6  °  C; 
 TRPV1 (485  bp): 5 ′ -TGTGCCGTTTCATGTTTGTC-3 ′ (forward), 5 ′ -
GTCGTCCTTGCCATCAGGT-3 ′ (reverse), 40 cycles and annealing 
temperature 55.9  °  C. 
 CB 2 (454  bp): 5 ′ -GGCAGCGTGACTATGACCTT-3 ′ (forward), 5 ′ -
AGCACTGGGAACCAACAGAT-3 ′ (reverse), 45 cycles and anneal-
ing temperature 57.3  °  C. 
 Standard-PCR was performed with 1  μ l of cDNA and specifi c 
primers (0.2  μ M forward and 0.2  μ M reverse) and 22.5  μ l of Ready 
Mix PCR Master Mix (Abgene) in a total volume of 25  μ l on a PCR 
Express thermal cycler. PCR conditions were as follows: 2  min at 
94  °  C for denaturation, followed by optimal cycles of 20  s at 94  °  C 
for denaturation, 30  s at the optimal annealing temperature, and 
40  s at 72  °  C for extension, with a fi nal elongation step of 10  min 
at 72  °  C. Negative controls without templates were performed to 
exclude the formation of primer dimers. All primer pairs pro-
duced a single specifi c band. PCR products were analyzed by 
electrophoresis on a 1  % agarose gel with ethidium bromide 
staining and photographed under UV transillumination. The 
products were sequenced by MWG Biotech (Ebersberg, Ger-
many) to confi rm their identity. 
 Real-time PCR 
 Quantitative real-time PCR was carried out in a fi nal volume of 
12.5  μ l consisting of 12.5 – 100  ng reverse-transcribed cDNA 
mixed with optimal concentrations of primers and probe and 
qPCR Core kit (Eurogentec, Southampton, UK) in 96-well plates 
on a Stratagene M  ×  3005P detector. The primer and probe sets 
were designed using Primer Express software (Applied Biosys-
tems) and synthesized commercially (Eurogentec). The sequence 
and optimal concentrations of primers and probes together with 
the size of products were as detailed previously for  β -actin, IL-6 
(interleukin 6), MCP-1 (monocyte chemotactic protein-1), TNF α 
(tumor necrosis factor-alpha), and ANGPTL4 (FIAF, angiopoietin-
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like protein 4)  [33,  34] . CB 1 , TRPV1, VEGF (vascular endothelial 
growth factor) and IL-1 β were as follows. 
 CB 1 : 5 ′ -CTCATTAAGACGGTGTTTGCATTC-3 ′ (forward), 5 ′ -CGT-
GTCGCAGGTCCTTACTC-3 ′ (reverse) and 5 ′ -FAM-TGCTCTGCCT-
GCTGAACTCCACCG-TAMRA-3 ′ (probe); 
 TRPV1: 5 ′ -TGCTGGCCTATGTAATTCTCACC-3 ′ (forward), 5 ′ -TCT-
TCTCCGTGTCCAGGATGG-3 ′ (reverse) and 5 ′ -FAM-CATCCTCCT-
GCTCAACATGCTCATCGCC-TAMRA-3 ′ (probe); 
 VEGF: 5 ′ -TGAGATCGAGTACATCTTCAAGCC-3 ′ (forward), 5 ′ -
GTGAGGTTTGATCCGCATAATCTG-3 ′ (reverse) and 5 ′ -FAM-CCT-
GTGTGCCCCTGATGCGATGCG-TAMRA-3 ′ (probe); 
 IL-1 β : 5 ′ -TGGCCCTAAACAGATGAAGTGC-3 ′ (forward), 5 ′ -GTAGT-
GGTGGTCGGAGATTCG-3 ′ (reverse) and 5 ′ -FAM-ACCTGGAC-
CTCTGCCCTCTGGATGG-TAMRA-3 ′ (probe). 
 Typically, the amplifi cation started with 2  min at 50  °  C, 10  min at 
95  °  C, and then 40 cycles of the following: 15  s at 95  °  C and 1  min 
at 60  °  C. 
 Human  β -actin was used as an endogenous reference; its expres-
sion remained unchanged both in response to the various treat-
ments and during preadipocyte diff erentiation. Relative 
quantitation values were expressed using the 2   −  Δ Δ Ct method 
(see User Bulletin 2, ABI PRISM 7700, pp 11 – 15, Applied Biosys-
tems) as fold changes in the target gene normalized to the refer-
ence gene ( β -actin) and related to the expression of the untreated 
controls. The PCR effi  ciency in all runs was close to 100  % , and all 
samples were analyzed in at least duplicate. 
 Measurement of adipokines by ELISA 
 IL-6, MCP-1, TNF α , and IL-1 β were measured in cell culture 
media among 8 other proteins using a commercial ELISA array 
for autoimmune disease (MEH-005A; SABiosciences Corpora-
tion, Frederick, USA). The assays were conducted in 96-well 
microplates, according to the manufacturer ’ s instructions. 
 Statistical analysis 
 The statistical signifi cance of diff erences between groups was 
assessed by Student ’ s  t -test. A p-value of   <  0.05 was considered 
to be statistically signifi cant. 
 Results 
 ▼ 
 Expression of cannabinoid receptor genes in 
diff erentiated adipocytes and preadipocytes 
 We fi rst investigated whether the human white adipocytes used 
here express the cannabinoid receptor genes when diff erenti-
ated in culture. RT-PCR was performed on mRNA from mature 
adipocytes (14 days post-induction). The results showed that 
the mRNAs for the genes encoding CB 1 and TRPV1 were present 
in the diff erentiated adipocytes at day 14 (  ● ▶  Fig.  1a by real time-
PCR), but CB 2 was not expressed in these cells (data not shown). 
The pattern of expression was the same for preadipocytes. CB 1 
and TRPV1 were also present in preadipocytes as shown in  ● ▶  Fig. 
 4a (vide infra) by real time-PCR; and CB 2 was not expressed in 
preadipocytes either (data not shown). The primers for CB 2 were 
previously tested with mRNA obtained from a human macro-
phage-like cell line (U937) as a positive control, attaining a clear 
signal, which was confi rmed by sequencing. 
 Upregulation of cannabinoid receptors, infl ammatory, 
and angiogenic genes by JTE-907 
 In pilot experiments, the eff ects of several CB 1 and CB 2 agonists 
and antagonists, at diff erent doses, on the expression of infl am-
mation-related genes in human adipocytes were examined and 
particularly strong responses were obtained with JTE-907 
(results not shown). In subsequent experiments, human preadi-
pocytes were diff erentiated and exposed to JTE-907 at day 14 
post-induction at which time they contained multiple lipid 
droplets. The mRNA levels of several genes were measured 20  h 
after exposing the human adipocytes to JTE-907 at 2 diff erent 
doses (1 and 10  μ M) (  ● ▶  Fig. 1 ). Firstly, 2 cannabinoid receptor 
genes (CB 1 and TRPV1) were analyzed (  ● ▶  Fig.  1a ). At 1  μ M no 
eff ect was found on the mRNA levels of the 2 receptors. At the 
second dose (10  μ M), CB 1  mRNA level was not signifi cantly 
changed and TRPV1 mRNA level was increased 3-fold. 
 Subsequently, the mRNA levels of infl ammatory markers (IL-6, 
MCP-1, TNF α , and IL-1 β ) and angiogenic factors (VEGF and 
ANGPTL4) were quantitated (  ● ▶  Fig.  1b ). The lowest dose (1  μ M) 
produced no eff ect on the mRNA level of any of the genes. The 
highest dose (10  μ M) increased IL-6, MCP-1, IL-1 β , VEGF, and 
ANGPTL4 mRNA levels by 41-, 7-, 6-, 6-, and 3-fold, respectively; 
however, this dose did not aff ect TNF α gene expression. 
4
Cont
JTE 1 µM
**
a
1
2
3 JTE 10 µM
Re
la
tiv
e 
m
RN
A 
le
ve
l
35
40
45
50
55
Cont
JTE 1 µM
JTE 10 µM
b
***
CB1 TRPV1
0
IL-6 MCP-1 TNFα IL-1β VEGF ANGPTL4
0
2
4
6
8
10
30
***
*** ***
**
Re
la
tiv
e 
m
RN
A 
le
ve
l
 Fig. 1  Eff ect of JTE-907 on gene expression in human adipocytes. 
Diff erentiated human adipocytes (14 days) were exposed for 20  h to 
JTE-907 (1 and 10  μ M).  a : CB 1 and TRPV1 gene expression.  b : Expression 
of infl ammatory marker genes and angiogenic factors. mRNA levels 
were normalized to human  β -actin and quantitated by real time-PCR. 
Means  ±  SE; n  =  6.  *  p  <  0.05,  * *  p  <  0.01 and  * * *  p  <  0.001 compared with 
control. JTE: JTE-907. 
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 Doses of 1 and 10  μ M of JTE-907 were used in vitro previously by 
another group  [14] , without damage to the cells, and a dose of 
50  μ M in our studies led to similar eff ects as 10  μ M. Exposure of 
diff erentiated human adipocytes (14 days) to JTE-907 at 10  μ M 
for 4  h did not result in any signifi cant change in the level of the 
mRNA for any of the genes mentioned previously (  ● ▶  Fig.  2a, b ). 
 IL-6, MCP-1, TNF α , and IL-1 β proteins were measured, in addi-
tion to 8 other proteins involved in autoimmune disease, in the 
medium using a commercial ELISA array in the cells incubated 
with 10  μ M JTE-907 for 20  h. The ELISA array showed a 2.6-fold 
increase in IL-6 release (  ● ▶  Fig.  2c ), which was statistically sig-
nifi cant, consistent with the mRNA measurements. The secre-
tion levels of other relevant proteins, such as TNF α and IL-1 β , 
were below the detection sensitivity of the array. There was no 
signifi cant change in MCP-1 release. 
 Eff ect of cannabinoid receptor antagonists on the 
response to JTE-907 
 The upregulation of several genes by JTE-907 (10  μ M for 20  h) on 
diff erentiated human adipocytes (14 days) was inhibited when 
AM251 (100  nM), a CB 1 receptor antagonist, was added at the 
same time (  ● ▶  Fig.  3a, b ). TRPV1 mRNA level was reduced 4-fold, 
although no signifi cant eff ect was found on CB 1 gene expression 
(  ● ▶  Fig.  3a ). The mRNA levels of IL-6, MCP-1, IL-1 β , VEGF, and 
ANGPTL4 decreased 29-fold, 5-fold, 3-fold, 6-fold and 3-fold, 
respectively; this antagonist did not aff ect TNF α gene expression 
(  ● ▶  Fig.  3b ). 
 Arachidonyl serotonin (A.S.), considered to be a TRPV1 and FAAH 
(degrading enzyme of anandamide) antagonist  [35] , partially 
inhibited the eff ect of JTE-907 on diff erentiated (14 days) human 
adipocytes when the 2 agents were added together (both at 
10  μ M for 20  h) (  ● ▶  Fig.  3c, d ). TRPV1 mRNA expression was 
reduced 3-fold, although no signifi cant eff ect was found on CB 1 
gene expression (  ● ▶  Fig.  3c ). The expression of IL-6, MCP-1, VEGF, 
and ANGPTL4 was signifi cantly lower than with JTE-907 alone, 
being 10-fold, 6-fold, 5-fold, and 4-fold lower, respectively; TNF α 
and IL-1 β gene expression remained unaltered (  ● ▶  Fig.  3d ). 
 Interestingly, AM630 (a CB 2 antagonist), partially upregulated 
the eff ect of JTE-907 alone (  ● ▶  Fig.  3e, f ). AM630 and JTE-907 
(both 10  μ M) were added simultaneously to diff erentiated 
human adipocytes and the cells were collected 20  h later. CB 1 
and TRPV1 mRNA levels were augmented 1.5-fold and 3-fold, 
respectively (  ● ▶  Fig.  3e ), while MCP-1 and ANGPTL4 expression 
was increased 2-fold and 4-fold, respectively (  ● ▶  Fig.  3f ). There 
was no eff ect of AM630 on IL-6, TNF α , IL-1 β , and VEGF gene 
expression (  ● ▶  Fig.  3f ). 
 Diff erential eff ects of JTE-907 on the expression of 
preadipocytes genes 
 The eff ect of JTE-907 on the expression in preadipocytes of those 
genes sensitive to the compound in adipocytes was then exam-
ined. Human preadipocytes were fed 14 days after reaching 
100  % confl uence and exposed to JTE-907 at 10  μ M for 20  h 
(  ● ▶  Fig. 4 ). Expression of the CB 1 receptor was slightly downreg-
ulated (56  % reduction) in preadipocytes with no signifi cant 
eff ect in mature adipocytes (  ● ▶  Fig.  4a ). The mRNA level of 2 
genes involved in infl ammation, MCP-1 and IL-1 β , was reduced 
by approximately 60  % in preadipocytes (  ● ▶  Fig.  4b ), which was 
in contrast to increases of more than 700  % and 600  % , respec-
tively, in mature adipocytes (  ● ▶  Fig.  1b ). 
 Discussion and Conclusions 
 ▼ 
 The high and growing incidence of obesity and its associated 
disorders now represents a major public health problem  [36] . 
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 Fig. 2  Eff ect of JTE-907 on gene expression and protein secretion in 
human adipocytes. Diff erentiated human adipocytes (14 days) were 
exposed to JTE-907 (10  μ M) for 4 and 20  h.  a : CB 1 and TRPV1 gene expres-
sion.  b : Expression of infl ammatory marker genes and angiogenic factors. 
mRNA levels were normalized to human  β -actin and quantitated by real 
time-PCR. Means  ±  SE, n  =  6.  * *  p  <  0.01 and  * * *  p  <  0.001 compared with 
control.  c : Secretion of IL-6 protein measured by ELISA. Diff erentiated hu-
man adipocytes (14 days) were exposed for 20  h to JTE-907 (10  μ M); n  =  3. 
Means  ±  SE.  * * *  p  <  0.001 compared with control. 
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The endocannabinoid system and its relation with metabolism, 
infl ammation, and angiogenesis have been considered as one of 
the key targets in the treatment of obesity and its comorbidities, 
among other diseases  [7,  18,  37,  38] . Cannabinoid receptors are 
mainly expressed in the central nervous system, but their 
peripheral location and eff ects are becoming of increasing inter-
est  [30,  39] . The present study has examined the eff ects of JTE-
907, a synthetic cannabinoid  [14] , on the expression of 2 
receptors of the ECS (CB 1 and TRPV1) and on the expression of 
major adipokine genes in preadipocytes and in mature adi-
pocytes. 
 White adipose tissue secretes a large number of protein signals 
and protein factors, termed adipokines. The production and cir-
culating level of some of these adipokines is increased in obese 
patients, for example IL-6, MCP-1, and TNF α  [25,  40] while their 
gene expression is reduced in adipose tissue after weight loss, as 
is the case with IL-1 β  [41] . The expression of some adipokines, 
such as leptin, VEGF, ANGPTL4  [32] , and RANTES (an immune 
mediator)  [42] , is increased under hypoxic conditions, and low 
oxygen tension has been proposed as a key trigger for the mild 
chronic infl ammatory state associated with obesity  [26] . Fur-
thermore, there is a link between these adipokines and the 
comorbidities associated with obesity  [43,  44] . 
 Within human white adipose tissue, CB 2 gene and protein expres-
sion in preadipocytes and mature adipocytes isolated from omen-
tal and subcutaneous tissue has been reported by some authors  [9] , 
while others  [11] were unable to detect CB 2 gene expression in adi-
pocytes and tissue from the subcutaneous fat depot. Our results are 
consistent with the latter, confi rming the expression of CB 1 and 
TRPV1, but not of CB 2 in human adipocytes. 
 The key fi ndings from the present study are that JTE-907 is able to 
regulate the expression of receptor genes, which are part of the ECS 
(CB 1 and TRPV1 receptors), together with a proinfl ammatory 
behavior and the upregulation of genes associated with angiogen-
esis (VEGF and ANGPTL4). Previous studies have shown that JTE-
907 has an anti-infl ammatory action in mouse cutaneous tissue 
 [14 – 17] , but no eff ect of JTE-907 has been found in human colon 
 [45] . In these investigations, JTE-907 was believed to be acting 
through the CB 2 receptor; however, in our study, due to the absence 
of expression of CB 2 receptors in human adipocytes the actions of 
this ligand are more likely to occur through CB 1 or TRPV1. 
 Therefore, the cells were exposed to an antagonist of CB 1 (AM-
251), CB 2 (AM-630) and TRPV1 and FAAH (arachidonoyl 
 serotonin) in diff erent experiments, in order to determine the 
probable route of action of JTE-907 within human white adi-
pocytes. Interestingly, the compound appeared to operate 
through CB 1 and TRPV1, either acting through both directly or 
through 1 receptor, which would subsequently activate the sec-
ond; the last mechanism has been demonstrated by other 
authors  [19,  46] . The importance of the TRPV1 receptor in obes-
ity is unclear, with 2 important studies showing contrasting 
results  [47,  48] . AM630, an antagonist or inverse agonist for CB 2 , 
which may act as an inverse agonist  [49] or weak partial agonist 
of the CB 1 receptor  [50] , augmented the eff ects obtained with 
JTE-907 alone in the case of genes such as CB 1 , TRPV1, MCP-1, 
and ANGPTL4. 
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 Fig. 3  Inhibition or upregulation of JTE-907 
eff ect on gene expression by antagonists of CB 1 , 
TRPV1 and CB 2 .  a and  b : Diff erentiated human adi-
pocytes (14 days) were exposed for 20  h to JTE-907 
(10  μ M) and JTE-907 (10  μ M)  +  AM251 (100  nM).  a . 
CB 1 and TRPV1 gene expression.  b : Expression of 
infl ammatory marker genes and angiogenic fac-
tors  c and  d : Diff erentiated human adipocytes (14 
days) were exposed for 20  h to JTE-907 (10  μ M) and 
JTE-907  +  A.S. (both 10  μ M).  c : CB 1 and TRPV1 gene 
expression.  d : Gene expression of infl ammatory 
markers and angiogenic factors  e and  f . Diff erenti-
ated human adipocytes (14 days) were exposed 
for 20  h to JTE-907 (10  μ M) and JTE-907  +  AM630 
(both 10  μ M).  e : CB 1 and TRPV1 gene expression. 
 f : Expression of infl ammatory marker genes and 
angiogenic factors. mRNA levels were normalized 
to human  β -actin. Means  ±  SE; n  =  6.  *  p  <  0.05 and 
 * *  p  <  0.01 compared with JTE-907. 
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 In a recent study, Hoareau et  al.  [51] reported anti-infl ammatory 
actions of SR141716 (also known as Rimonabant, a CB 1 antago-
nist) and SR144528 (a CB 2 antagonist) against LPS stimulation in 
mature adipocytes obtained from human subcutaneous adipose 
tissue, with stronger eff ects with the latter. These and other 
recent results confi rming the anti-infl ammatory actions of a CB 1 
antagonist like Rimonabant  [30,  52] , may support the idea that 
AM630 and JTE-907 are exerting their proinfl ammatory actions 
as agonists of CB 1 . In addition, there is evidence relating some 
CB 1 agonists with anti-infl ammatory actions, such as WIN55,212-
2  [53,  54] , ACEA  [55] or anandamide (CB 1 and CB 2 agonist)  [56] , 
or with proinfl ammatory actions, like anandamide  [57] . This 
confi rms the fact that diff erent or even the same, endocannabi-
noids may work in opposite ways. The increased secretion of IL-
6 protein in response to JTE-907 underlines the proinfl ammatory 
property of this compound in human adipocytes and indicates 
that the changes in gene expression are refl ected by parallel 
alterations in the amount of the encoded protein. 
 The relationship between angiogenesis and JTE-907 has not 
been described previously. Furthermore, it is the fi rst time this 
synthetic cannabinoid has been found to upregulate the expres-
sion of genes associated with a proinfl ammatory state and to 
have a proangiogenic eff ect. The receptors, CB 1 and TRPV1, have 
been linked to infl ammation and cardiovascular responses 
 [18,  19] . This would indicate that in adipocytes JTE-907 might be 
acting as an agonist for these receptors. 
 There is increasing recognition of the importance of other cells, 
apart from mature adipocytes, in the function of white adipose 
tissue, including infl ammation. This is particularly evident with 
respect to macrophages which are recruited during the expan-
sion of adipose mass in obesity, and this is considered to be a key 
component of the infl ammatory response. Preadipocytes are 
also increasingly recognized to be major players in adipose tis-
sue infl ammation  [58,  59] . However, JTE-907 did not aff ect in 
preadipocytes those same genes that were upregulated in the 
mature adipocytes. In practise, for those genes in preadipocytes 
that were infl uenced by the treatment, there was a downregula-
tion in contrast to the upregulation in the mature adipocytes. 
Previous studies have shown that the preadipocytes may show a 
similar, or opposite, behavior to mature adipocytes, depending 
on the parameter  [60,  61] . 
 Infl ammation and angiogenesis are key processes in obesity, the 
metabolic syndrome, and a number of other diseases. The 
present study suggests that CB 1 and TRPV1 receptors participate 
in the regulation of the expression of several important infl am-
matory and angiogenic gene factors in human mature adi-
pocytes. Understanding the mechanism of action of the diff erent 
cannabinoid receptors within adipose tissue and other periph-
eral sites may be valuable in the development of pharmacologi-
cal treatments for obesity-associated diseases. 
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